192 related articles for article (PubMed ID: 27262335)
1. The Impact of Antiplatelet Treatment on Endothelial Function.
Androulakis E; Norrington K; Bakogiannis C; Lioudaki E; Siasos G; Tousoulis D
Curr Pharm Des; 2016; 22(29):4512-4518. PubMed ID: 27262335
[TBL] [Abstract][Full Text] [Related]
2. From pathophysiology to targeted therapy for atherothrombosis: a role for the combination of statin and aspirin in secondary prevention.
Chapman MJ
Pharmacol Ther; 2007 Jan; 113(1):184-96. PubMed ID: 17070923
[TBL] [Abstract][Full Text] [Related]
3. Effects of endothelial dysfunction on residual platelet aggregability after dual antiplatelet therapy with aspirin and clopidogrel in patients with stable coronary artery disease.
Fujisue K; Sugiyama S; Ono T; Matsuzawa Y; Akiyama E; Sugamura K; Matsubara J; Kurokawa H; Kaikita K; Iwashita S; Sumida H; Hokimoto S; Oniki K; Nakagawa K; Matsui K; Ogawa H
Circ Cardiovasc Interv; 2013 Aug; 6(4):452-9. PubMed ID: 23922147
[TBL] [Abstract][Full Text] [Related]
4. Endothelial dysfunction and cardiovascular risk factors.
Grover-Páez F; Zavalza-Gómez AB
Diabetes Res Clin Pract; 2009 Apr; 84(1):1-10. PubMed ID: 19185380
[TBL] [Abstract][Full Text] [Related]
5. Platelet-mediated inflammation in cardiovascular disease. Potential role of platelet-endothelium interactions.
Tsoumani ME; Kalantzi KI; Goudevenos IA; Tselepis AD
Curr Vasc Pharmacol; 2012 Sep; 10(5):539-49. PubMed ID: 22338568
[TBL] [Abstract][Full Text] [Related]
6. The role of adenosine 5'-diphosphate receptor blockade in patients with cardiovascular disease.
Solet DJ; Zacharski LR; Plehn JF
Am J Med; 2001 Jul; 111(1):45-53. PubMed ID: 11448660
[TBL] [Abstract][Full Text] [Related]
7. Use of antiplatelet agents in sepsis: a glimpse into the future.
Akinosoglou K; Alexopoulos D
Thromb Res; 2014 Feb; 133(2):131-8. PubMed ID: 24103487
[TBL] [Abstract][Full Text] [Related]
8. Clopidogrel response variability is associated with endothelial dysfunction in coronary artery disease patients receiving dual antiplatelet therapy.
Siasos G; Oikonomou E; Zaromitidou M; Kioufis S; Kokkou E; Mourouzis K; Vlasis K; Vavuranakis M; Stone PH; Papavassiliou AG; Tousoulis D
Atherosclerosis; 2015 Sep; 242(1):102-8. PubMed ID: 26188531
[TBL] [Abstract][Full Text] [Related]
9. Glycoprotein IIb/IIIa receptor antagonists: clinical pharmacology in cardiovascular diseases of aging.
Sebastian M; Makkar R
Drugs Aging; 1999 Sep; 15(3):207-18. PubMed ID: 10503813
[TBL] [Abstract][Full Text] [Related]
10. Platelet glycoprotein IIb/IIIa receptor blockade improves vascular nitric oxide bioavailability in patients with coronary artery disease.
Heitzer T; Ollmann I; Köke K; Meinertz T; Munzel T
Circulation; 2003 Aug; 108(5):536-41. PubMed ID: 12874186
[TBL] [Abstract][Full Text] [Related]
11. The antiplatelet effects of nitrates: is it of clinical significance in patients with cardiovascular disease?
Zhou RH; Frishman WH
Cardiol Rev; 2010; 18(4):198-203. PubMed ID: 20539103
[TBL] [Abstract][Full Text] [Related]
12. Clinical evidence for anti-inflammatory effects of antiplatelet therapy in patients with atherothrombotic disease.
Steinhubl SR; Badimon JJ; Bhatt DL; Herbert JM; Lüscher TF
Vasc Med; 2007 May; 12(2):113-22. PubMed ID: 17615799
[TBL] [Abstract][Full Text] [Related]
13. Effects of antihypertensive drugs on endothelial dysfunction: clinical implications.
Taddei S; Virdis A; Ghiadoni L; Sudano I; Salvetti A
Drugs; 2002; 62(2):265-84. PubMed ID: 11817973
[TBL] [Abstract][Full Text] [Related]
14. Novel therapeutic targets for preserving a healthy endothelium: strategies for reducing the risk of vascular and cardiovascular disease.
Ramli J; CalderonArtero P; Block RC; Mousa SA
Cardiol J; 2011; 18(4):352-63. PubMed ID: 21769815
[TBL] [Abstract][Full Text] [Related]
15. Antiplatelet therapies: platelet GPIIb/IIIa antagonists and beyond.
Mousa SA
Curr Pharm Des; 2003; 9(28):2317-22. PubMed ID: 14529393
[TBL] [Abstract][Full Text] [Related]
16. The expanding role of antiplatelet agents in coronary artery disease. A current review of aspirin, glycoprotein IIb/IIIa inhibitors, and the thienopyridines.
Hostetter JC; Bhatt DL
Minerva Cardioangiol; 2003 Oct; 51(5):531-46. PubMed ID: 14551522
[TBL] [Abstract][Full Text] [Related]
17. The P2Y12 receptor as a therapeutic target in cardiovascular disease.
Storey RF
Platelets; 2001 Jun; 12(4):197-209. PubMed ID: 11454254
[TBL] [Abstract][Full Text] [Related]
18. The platelet in diabetes: focus on prevention of ischemic events.
Colwell JA; Nesto RW
Diabetes Care; 2003 Jul; 26(7):2181-8. PubMed ID: 12832332
[TBL] [Abstract][Full Text] [Related]
19. Nano-medicine and Vascular Endothelial Dysfunction: Options and Delivery Strategies.
Taneja G; Sud A; Pendse N; Panigrahi B; Kumar A; Sharma AK
Cardiovasc Toxicol; 2019 Feb; 19(1):1-12. PubMed ID: 30448914
[TBL] [Abstract][Full Text] [Related]
20. [Endothelial dysfunction and metabolic effects of nitric oxide in human].
Kolesnichenko OIu; Filatova LM; Krivitsina ZA; Voronkov IuI
Fiziol Cheloveka; 2003; 29(5):74-81. PubMed ID: 14611088
[No Abstract] [Full Text] [Related]
[Next] [New Search]
